Once‐a‐Day Treatment with Sotalol and Hydrochlorothiazide in Patients with Essential Hypertension

A preliminary report is given on the first 500 patients entered in an on-going open study in general practice of a combination of 10 mg timolol maleate and 2.5 mg bendrofluazide used to treat mild to moderate essential hypertension. After a 2-week placebo period, dose titration was conducted at weekly intervals, with a final assessment 8 weeks after the diastolic blood pressure was controlled. Data for 472 patients out of 492 commencing active therapy were evaluated. Four-hundred and thirty-seven (93%) became normotensive (less than or equal to mmHg diastolic) on a mean dose of 1.9 tablets taken as a single daily dose. Control was maintained over the follow-up period in all but 13 (2.6%) patients who required a dosage reduction and 2 (0.4%) who required a dosage increase. The incidence of side-effects was low, 22 (4.4%) patients stopping treatment due to adverse events. Biochemical parameters all stayed within normal values. The rapidity of dosage titration, patient acceptability, compliance with regard to the once daily dosage and the low incidence of side-effects suggest that the timolol/bendrofluazide combination approaches optimum therapy for mild to moderate hypertension.

show abstract

Sotalol

Singh

Deedwania

Nademanee

et al. 1987

Drugs

View full text Add to dashboard Cite

Sotalol is a beta-adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardioselectivity. It lengthens repolarisation and the effective refractory period in all cardiac tissues independently of its antiadrenergic properties. Combining Class II and Class III antiarrhythmic properties, sotalol can be given either intravenously or orally and its pharmacokinetic properties permit long dosing (once or twice daily) intervals. Controlled and uncontrolled studies have established the efficacy of sotalol in mild-to-moderate essential hypertension and in angina of effort. Sotalol reduces anginal frequency and glyceryl trinitrate (nitroglycerin) consumption and increases exercise capacity during treadmill stress tests. In addition, although there is evidence that the drug reduces reinfarction rate in survivors of acute infarction, the data for reduction in sudden death rates in these patients are not as compelling as for other beta-blockers. However, comparative and additional long term studies are required before an accurate assessment of the use of sotalol in these disorders can be made. When used in the treatment of mild-to-moderate hypertension sotalol is more effective than placebo and comparable to other beta-blockers in reducing elevated blood pressures. In addition, a synergistic antihypertensive response is achieved when sotalol is combined with hydrochlorothiazide. Still, additional well-controlled comparative studies are required before the value of sotalol relative to other drug treatment regimens in the management of hypertension can be made. In preliminary studies sotalol appeared effective in most forms of supraventricular tachyarrhythmias with its effects being similar to those of other beta-blockers. However, preliminary data indicate that sotalol is likely to be more effective than than conventional beta-blockers in converting atrial flutter and fibrillation to sinus rhythm and maintaining stability post-conversion. Sotalol also appears to be a promising agent in the control of ventricular arrhythmias. In suppressing premature ventricular contractions it is at least as effective as procainamide. In ventricular tachycardia and fibrillation, intravenous sotalol (1.5 mg/kg), prevents reinduction by programmed electrical stimulation in 40 to 50% of cases if double stimuli are used. Both prevention of reinducible arrhythmia and the suppression of spontaneous arrhythmias on Holter recordings are predictive of a long term favourable clinical outcome. In patients with reduced ejection fractions, sotalol depresses ventricular function less than conventional beta-blockers.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Once‐a‐Day Treatment with Sotalol and Hydrochlorothiazide in Patients with Essential Hypertension

Cited by 3 publications

References 10 publications

Reversible vestibular dysfunction secondary to sotalol use

Reversible vestibular dysfunction secondary to sotalol use

A multi-centre general practice study on the use of a timolol/bendrofluazide combination (‘Prestim’) in the management of hypertension: preliminary report

Sotalol

Contact Info

Product

Resources

About